US-based COUR Pharmaceutical has announced a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize COUR’s proprietary tolerogenic nanoparticle treatments aimed at addressing an autoimmune disease.
Financial Terms and Milestones of the Agreement
According to the agreement, COUR is set to receive upfront and near-term milestones totaling USD 40 million. Additionally, the company is eligible for development, commercial, and net sales milestone payments that could exceed USD 900 million, along with tiered royalties on net sales. This significant investment underscores the potential impact of COUR’s nanoparticle technology in the treatment of autoimmune diseases.
Responsibilities and Contributions of Both Parties
COUR will take the lead on preclinical development and the technical transfer of manufacturing processes, leveraging its expertise in tolerogenic nanoparticle technology. Genentech, with its extensive experience in clinical development and regulatory affairs, will be responsible for advancing the clinical development, filing for regulatory approval, and ultimately commercializing the treatments.-Fineline Info & Tech
